SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours

Launched by IMPERIAL COLLEGE LONDON · Mar 22, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a type of ovarian cancer known as malignant ovarian germ cell tumors (MOGCT). The researchers want to understand how certain tiny molecules in the blood, called microRNAs, behave in patients with this cancer compared to those with benign (non-cancerous) ovarian germ cell tumors (BOGCT) or no ovarian health issues. They will also study how these tumors appear on imaging tests like ultrasounds and MRIs, and whether changes in microRNA levels can help predict treatment responses or cancer relapses.

To participate, women aged 16 and older who have recently been diagnosed with a malignant ovarian germ cell tumor may be eligible. Those with benign tumors or no gynecological problems can also join as a control group. Participants will have regular blood tests to track their microRNA levels and may provide tumor samples during surgery if needed. The researchers will then compare the findings to see how MOGCTs differ from benign tumors. Importantly, this study is not yet recruiting participants, so it’s a good idea to talk to a healthcare provider for more information.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • All patients with a new diagnosis of a malignant ovarian germ cell tumour.
• • The control population will include all patients with a new diagnosis of a benign ovarian germ cell tumour or no known gynaecological pathology.
• Exclusion Criteria:
• • Previous or ongoing chemotherapy for MOGCT
• • Previous surgery for MOGCT
• • Pregnancy - this will be verbally communicated for those not having surgery or chemotherapy, for those having surgery or chemotherapy a urine pregnancy test should be negative and documented in the clinical notes.
• • Fetal circulating DNA is known to be present in maternal blood and therefore pregnant women should not be included in this study
• • Denial of informed consent
• • Age \<16 years
• • History of any other cancer